Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD

American Journal of Kidney Diseases

Volumn 69, Issue 6, 2017, Pages 815-826

  Gupta, Nupur ^a   Wish, Jay B ^a  

^a INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

Anemia; chronic kidney disease (CKD); daprodustat; erythropoietin; functional iron deficiency; hemoglobin; hypoxia; hypoxia inducible factor prolyl hydroxylase inhibitor; molidustat; review; roxadustat; vadadustat

Indexed keywords

ANTIANEMIC AGENT; DAPRODUSTAT; ENALAPRIL; FG 2216; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR; IRON; MOLIDUSTAT; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ROXADUSTAT; UNCLASSIFIED DRUG; VADADUSTAT; BARBITURIC ACID DERIVATIVE; ENZYME INHIBITOR; ERYTHROPOIETIN; FG-4592; GLYCINE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; ISOQUINOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANEMIA; ANGIOGENESIS; ANTIHYPERTENSIVE ACTIVITY; CHRONIC KIDNEY FAILURE; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IRON METABOLISM; NAUSEA; NONHUMAN; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMPLICATION; METABOLISM;

ANEMIA; BARBITURATES; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; ERYTHROPOIETIN; GLYCINE; HUMANS; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; ISOQUINOLINES; PYRAZOLES; RENAL INSUFFICIENCY, CHRONIC; TRIAZOLES;

EID: 85013639183     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.12.011     Document Type: Review

References (68)

1. Semenza, G.L., Wang, G.L., A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12:12 (1992), 5447–5454.
2. Takeuchi, M., Kobata, A., Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology 1:4 (1991), 337–346.
3. Stone, W.J., Graber, S.E., Krantz, S.B., et al. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial. Am J Med Sci 296:3 (1988), 171–179.
4. Singh, A.K., Szczech, L., Tang, K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:20 (2006), 2085–2098.
5. Drueke, T.B., Locatelli, F., Clyne, N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:20 (2006), 2071–2084.
6. Bonomini, M., Del Vecchio, L., Sirolli, V., Locatelli, F., New treatment approaches for the anemia of CKD. Am J Kidney Dis 67:1 (2016), 133–142.
7. 2 tension. Proc Natl Acad Sci U S A 92:12 (1995), 5510–5514.
8. 2-regulated prolyl hydroxylation. Science 292:5516 (2001), 468–472.
9. 2 sensing. Science 292:5516 (2001), 464–468.
10. Vogel, S., Wottawa, M., Farhat, K., et al. Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent cofilin phosphorylation. J Biol Chem 285:44 (2010), 33756–33763.
11. Lee, D.C., Sohn, H.A., Park, Z.Y., et al. A lactate-induced response to hypoxia. Cell 161:3 (2015), 595–609.
12. Lando, D., Peet, D.J., Whelan, D.A., Gorman, J.J., Whitelaw, M.L., Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295:5556 (2002), 858–861.
13. Lando, D., Peet, D.J., Gorman, J.J., Whelan, D.A., Whitelaw, M.L., Bruick, R.K., FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16:12 (2002), 1466–1471.
14. Tanaka, T., Nangaku, M., Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res 318:9 (2012), 1068–1073.
15. Rosenberger, C., Mandriota, S., Jurgensen, J.S., et al. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 13:7 (2002), 1721–1732.
16. Epstein, A.C., Gleadle, J.M., McNeill, L.A., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:1 (2001), 43–54.
17. Masson, N., Willam, C., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J., Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20:18 (2001), 5197–5206.
18. Takeda, K., Ho, V.C., Takeda, H., Duan, L.J., Nagy, A., Fong, G.H., Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol 26:22 (2006), 8336–8346.
19. Takeda, K., Cowan, A., Fong, G.H., Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 116:7 (2007), 774–781.
20. Lankhorst, C.E., Wish, J.B., Anemia in renal disease: diagnosis and management. Blood Rev 24:1 (2010), 39–47.
21. Kapitsinou, P.P., Liu, Q., Unger, T.L., et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 116:16 (2010), 3039–3048.
22. Rolfs, A., Kvietikova, I., Gassmann, M., Wenger, R.H., Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 272:32 (1997), 20055–20062.
23. Bianchi, L., Tacchini, L., Cairo, G., HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res 27:21 (1999), 4223–4227.
24. Tacchini, L., Bianchi, L., Bernelli-Zazzera, A., Cairo, G., Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem 274:34 (1999), 24142–24146.
25. Mastrogiannaki, M., Matak, P., Keith, B., Simon, M.C., Vaulont, S., Peyssonnaux, C., HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest 119:5 (2009), 1159–1166.
26. Peyssonnaux, C., Zinkernagel, A.S., Schuepbach, R.A., et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117:7 (2007), 1926–1932.
27. Liu, Q., Davidoff, O., Niss, K., Haase, V.H., Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest 122:12 (2012), 4635–4644.
28. Takubo, K., Goda, N., Yamada, W., et al. Regulation of the HIF-1alpha level is essential for hematopoietic stem cells. Cell Stem Cell 7:3 (2010), 391–402.
29. Forristal, C.E., Winkler, I.G., Nowlan, B., Barbier, V., Walkinshaw, G., Levesque, J.P., Pharmacologic stabilization of HIF-1alpha increases hematopoietic stem cell quiescence in vivo and accelerates blood recovery after severe irradiation. Blood 121:5 (2013), 759–769.
30. Besarab, A., Provenzano, R., Hertel, J., et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant 30:10 (2015), 1665–1673.
31. Besarab, A., Chernyavskaya, E., Motylev, I., et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol 27:4 (2016), 1225–1233.
32. Provenzano, R., Besarab, A., Sun, C.H., et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol 11:6 (2016), 982–991.
33. Pergola, P.E., Spinowitz, B.S., Hartman, C.S., Maroni, B.J., Haase, V.H., Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int 90:5 (2016), 1115–1122.
34. Seeley, T.W., Novel and beneficial pharmacodynamic properties of endogenous EPO and ‘complete erythropoiesis’ induced by selective HIF prolyl hydroxylase inhibitors. [abstract] J Am Soc Nephrol, 16, 2005, 761A.
35. Klaus, S., Langsetmo, T., Neff, A., Liu, D., Beneficial pharmacodynamic effects resulting from ‘complete erythropoiesis’ induced by novel HIF prolyl hydroxylase inhibitors FG-2216 and FG-4592. [abstract] J Am Soc Nephrol, 19, 2008, 524A.
36. Eltzschig, H.K., Bratton, D.L., Colgan, S.P., Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat Rev Drug Discov 13:11 (2014), 852–869.
37. Besarab, A., Hulter, H.N., Klaus, S., et al. FG-4592, a novel oral HIF prolyl hydroxylase inhibitor, elevates hemoglobin in anemic stage 3/4 CKD patients. [abstract] J Am Soc Nephrol, 21, 2010, 95A.
38. Groenendaal-van de Meent, D., Adel, M., Noukens, J., et al. Effect of moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Clin Drug Investig 36:9 (2016), 743–751.
39. Besarab, A., Chernyavskaya, E., Motylev, I., et al. FG-4592, an oral hypoxia-inducible factor prolyl hydroxylase-inhibitor, corrects anemia without iron supplementation in incident dialysis patients. [abstract] J Am Soc Nephrol, 23, 2012, 21A.
40. Provenzano, R., Besarab, A., Wright, S., et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67:6 (2016), 912–924.
41. Szczech, L.H., Besarab, A., Saikali, K.G., Poole, L., Yu, K.H.P., Neff, T.B., TH-OR039 anemia correction with roxadustat improves health related quality of life (HRQOL) in chronic kidney disease (CKD) patients. [abstract] J Am Soc Nephrol, 2015 Supplement 26:11A.
42. Szczech, L., Besarab, A., Saikali, K.G., et al. TH-PO648 anemia correction with roxadustat lowers cholesterol in chronic kidney disease (CKD) patients. [abstract] J Am Soc Nephrol, 2015 Supplement 26:237A.
43. Shalwitz, R., Hartman, C., Flinn, C., Shalwitz, I., Logan, D.K., AKB-6548, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor reduces hepcidin and ferritin while it increases reticulocyte production and total iron binding capacity in healthy adults. [abstract] J Am Soc Nephrol, 22, 2011, 45A.
44. Shalwitz, R., Hartman, C., Flinn, C., et al. AKB-6548, a new hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin in chronic kidney disease patients without increasing basal erythropoietin levels. [abstract] J Am Soc Nephrol, 23, 2012, 56A.
45. Hartman, C., Smith, M.T., Flinn, C., et al. AK-6548 a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia. [abstract] J Am Soc Nephrol, 22, 2011, 435A.
46. Haase, V.H., Hartman, C.S., Maroni, B.J., Farzeneh-Far, R., McCullough, P.A., Vadadustat, a novel, oral treatment for anemia of chronic kidney disease, maintains stable hemoglobin levels in dialysis patients converting from erythropoiesis-stimulating agents [abstract]. J Am Soc Nephrol, 26, 2016, B8.
47. Hara, K., Takahashi, N., Wakamatsu, A., Caltabiano, S., Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet 30:6 (2015), 410–418.
48. Holdstock, L., Meadowcroft, A.M., Maier, R., et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol 27:4 (2016), 1234–1244.
49. Brigandi, R.A., Johnson, B., Oei, C., et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am J Kidney Dis 67:6 (2016), 861–871.
50. Johnson, B.M., Stier, B.A., Caltabiano, S., Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. Clin Pharmacol Drug Dev 3:2 (2014), 109–117.
51. Flamme, I., Oehme, F., Ellinghaus, P., Jeske, M., Keldenich, J., Thuss, U., Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (molidustat) stimulates erythropoietin production without hypertensive effects. PloS One, 9(11), 2014, e111838.
52. Boettcher, M.F., Lentini, S., Kaiser, A., Flamme, I., Kubitza, D., Wensing, G., First-in-man study with BAY 85-3934—a new oral selective HIF-PH inhibitor for the treatment of renal anemia. [abstract] J Am Soc Nephrol, 24, 2013, 347A.
53. Macdougall, I.C., Akizawa, T., Berns, J., Lentini, S., Bernhardt, T., Molidustat increases hemoglobin in erythropoiesis stimulating agents (ESA) - naive anaemic patients with chronic kidney diseases not on dialysis (CKD-ND). Nephrol Dial Transplant 31:suppl 1 (2016), i15–i17.
54. Amgen. ARANESP® (darbepoetin alfa) injection, for intravenous or subcutaneous use. http://pi.amgen.com/united_states/aranesp/ckd/aranesp_pi_hcp_english.pdf. Accessed February 14, 2017.
55. Amgen. Epogen® (epoetin alfa) injection, for intravenous or subcutaneous use. http://pi.amgen.com/united_states/epogen/epogen_pi_hcp_english.pdf. Accessed February 14, 2017.
56. Kanbay, M., Perazella, M.A., Kasapoglu, B., Koroglu, M., Covic, A., Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management. Blood Purif 29:1 (2010), 1–12.
57. Ganz, T., Hepcidin and the global burden of iron deficiency. Clin Chem 61:4 (2015), 577–578.
58. Ashby, D.R., Gale, D.P., Busbridge, M., et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75:9 (2009), 976–981.
59. Onuma, S., Honda, H., Kobayashi, Y., et al. Effects of long-term erythropoiesis-stimulating agents on iron metabolism in patients on hemodialysis. Ther Apher Dial 19:6 (2015), 582–589.
60. Volke, M., Gale, D.P., Maegdefrau, U., et al. Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors. PloS One, 4(11), 2009, e7875.
61. Kautz, L., Jung, G., Valore, E.V., Rivella, S., Nemeth, E., Ganz, T., Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46:7 (2014), 678–684.
62. Goel, H.L., Mercurio, A.M., VEGF targets the tumour cell. Nat Rev Cancer 13:12 (2013), 871–882.
63. Krock, B.L., Skuli, N., Simon, M.C., Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2:12 (2011), 1117–1133.
64. Besarab, A., Provenzano, R., Fishbane, S., et al. FG-4592 Oralhypoxia-inducible factor prolyl hydroxylase inhibitor corrects anemia in nondialysis CKD patients without IV iron. [abstract] J Am Soc Nephrol, 22, 2011, 196A.
65. Qian, J., Chen, N., Chen, J., et al. FR-OR011 A randomized, double-blind, placebo controlled trial of FG-4592 for correction of anemia in subjects with chronic kidney disease in China. [abstract] JASN Kidney Week, 2013 Supplement 24:38A.
66. Roger, S., Bock, A., Carrera, F., et al. SO048 IV ferric carboxymaltose (FCM) is a convenient and well-tolerated first-line therapy for the treatment of anaemia in patients with iron deficiency and non-dialysis dependent chronic kidney disease (ND-CKD): results of the randomised find-CKD study. Nephrol Dial Transplant(suppl 3), 2014, ii21–ii22.
67. Endo, Y., Kohno, T., Imai, Y., et al. SA-P0819 A 4-week dose response study of the hypoxia inducible factor-prolyl hydroxylase inhibitor GSK1278863 in Japanese anemic hemodialysis subjects. [abstract] J Am Soc Nephrol(suppl 26), 2015, 818A.
68. Macdougall, I.C., Akizawa, T., Berns, J., Lentini, S., Bernhardt, T., Krüger, T., SP309 Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND) [abstract]. Nephrol Dial Transplant, 31(suppl 1), 2016.